Press coverage about Covance (NYSE:CVD) has been trending somewhat positive on Friday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Covance earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media headlines about the healthcare company an impact score of 45.4156226752693 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/10/27/covance-cvd-receiving-somewhat-favorable-media-coverage-report-shows.html.

About Covance

Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.

Insider Buying and Selling by Quarter for Covance (NYSE:CVD)

Receive News & Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related companies with MarketBeat.com's FREE daily email newsletter.